American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients.
暂无分享,去创建一个
F. Dentali | H. Schünemann | M. Cushman | S. Kahn | F. Spencer | N. Zakai | K. Bauer | I. Neumann | W. Wiercioch | G. P. Morgano | S. Rezende | A. Darzi | S. Balduzzi | R. Nieuwlaat | J. Yepes-Nuñez | Yuan Zhang | J. Beyer-Westendorf | Allison E. Burnett | Jill Lansing
[1] Gilbert GREUB,et al. Venous thromboembolism in critically Ill patients with COVID‐19: Results of a screening study for deep vein thrombosis , 2020, Research and Practice in Thrombosis and Haemostasis.
[2] G. Raskob,et al. Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness , 2018, The New England journal of medicine.
[3] Francesca N. Delling,et al. Heart Disease and Stroke Statistics—2018 Update: A Report From the American Heart Association , 2018, Circulation.
[4] G. Gartlehner,et al. [GRADE: Evidence to Decision (EtD) frameworks - a systematic and transparent approach to making well informed healthcare choices. 1: Introduction]. , 2018, Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen.
[5] R. Yusen,et al. The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification , 2017, TH Open.
[6] P. Prandoni,et al. Scoring Systems for Estimating Risk of Venous Thromboembolism in Hospitalized Medical Patients , 2017, Seminars in Thrombosis and Hemostasis.
[7] N. Kucher,et al. Risk assessment models for venous thromboembolism in acutely ill medical patients. A systematic review. , 2017, Thrombosis and haemostasis.
[8] D. D. De Silva,et al. Asian venous thromboembolism guidelines: updated recommendations for the prevention of venous thromboembolism. , 2017, International angiology : a journal of the International Union of Angiology.
[9] Alonso Carrasco-Labra,et al. GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT. , 2017, Journal of clinical epidemiology.
[10] V. Chopra,et al. Validation of Risk Assessment Models of Venous Thromboembolism in Hospitalized Medical Patients. , 2016, The American journal of medicine.
[11] T. McGinn,et al. External validation of the IMPROVE Bleeding Risk Assessment Model in medical patients , 2016, Thrombosis and Haemostasis.
[12] Elie A Akl,et al. GRADE Guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health. , 2016, Journal of clinical epidemiology.
[13] G. Guyatt,et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines , 2016, British Medical Journal.
[14] Gordon H Guyatt,et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction , 2016, British Medical Journal.
[15] G. Raskob,et al. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE , 2016, Thrombosis and Haemostasis.
[16] B. Wiens,et al. Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. , 2016, The New England journal of medicine.
[17] J. Collen,et al. Validation of the International Medical Prevention Registry on Venous Thromboembolism Bleeding Risk Score. , 2016, Chest.
[18] Compression stockings for preventing deep vein thrombosis in airline passengers. , 2016, The Cochrane database of systematic reviews.
[19] J. Bosch,et al. Nadroparin for the prevention of venous thromboembolism in nonsurgical patients: a systematic review and meta-analysis , 2016, Journal of Thrombosis and Thrombolysis.
[20] Holger J Schünemann,et al. Guidelines International Network: Principles for Disclosure of Interests and Management of Conflicts in Guidelines. , 2015, Annals of internal medicine.
[21] J. Kai,et al. A randomised controlled trial of the clinical effectiveness and cost-effectiveness of the levonorgestrel-releasing intrauterine system in primary care against standard treatment for menorrhagia: the ECLIPSE trial. , 2015, Health technology assessment.
[22] P. Sandercock,et al. The Clots in Legs Or sTockings after Stroke (CLOTS) 3 trial: a randomised controlled trial to determine whether or not intermittent pneumatic compression reduces the risk of post-stroke deep vein thrombosis and to estimate its cost-effectiveness. , 2015, Health technology assessment.
[23] A. Gruber,et al. Excess of heme induces tissue factor-dependent activation of coagulation in mice , 2015, Haematologica.
[24] M. Tirani,et al. [Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise]. , 2015, Recenti progressi in medicina.
[25] D. Kendoff,et al. Are patients with preoperative air travel at higher risk for venous thromboembolism following primary total hip and knee arthroplasty? , 2015, Technology and health care : official journal of the European Society for Engineering and Medicine.
[26] G. Guyatt,et al. Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients. , 2014, JAMA.
[27] A. Eichorn,et al. External Validation of the Risk Assessment Model of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) for Medical Patients in a Tertiary Health System , 2014, Journal of the American Heart Association.
[28] G. Guyatt,et al. Considering intellectual, in addition to financial, conflicts of interest proved important in a clinical practice guideline: a descriptive study. , 2014, Journal of clinical epidemiology.
[29] V. Chopra,et al. Hospital performance for pharmacologic venous thromboembolism prophylaxis and rate of venous thromboembolism : a cohort study. , 2014, JAMA internal medicine.
[30] H. Büller,et al. The incidence of venous thromboembolism in commercial airline pilots: a cohort study of 2630 pilots , 2014, Journal of thrombosis and haemostasis : JTH.
[31] R. Joshi,et al. Thrombo-prophylaxis in acutely ill medical and critically ill patients , 2014, Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine.
[32] R. Berger,et al. Risk of symptomatic venous thromboembolism associated with flying in the early postoperative period following elective total hip and knee arthroplasty. , 2014, The Journal of arthroplasty.
[33] J. Gurwitz,et al. Venous thromboembolism in older adults: A community-based study. , 2014, The American journal of medicine.
[34] A. Cohen,et al. Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction). , 2014, The Cochrane database of systematic reviews.
[35] H. Büller,et al. The risk of venous thrombosis after air travel: contribution of clinical risk factors , 2014, British journal of haematology.
[36] A. Mebazaa,et al. D‐dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial , 2014, Journal of thrombosis and haemostasis : JTH.
[37] Romina Brignardello-Petersen,et al. Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise , 2014, Canadian Medical Association Journal.
[38] D. Aujesky,et al. Multicentre validation of the Geneva Risk Score for hospitalised medical patients at risk of venous thromboembolism , 2013, Thrombosis and Haemostasis.
[39] L. Jeyaseelan,et al. Randomised controlled trial for efficacy of unfractionated heparin (UFH) versus low molecular weight heparin (LMWH) in thrombo-prophylaxis. , 2013, The Journal of the Association of Physicians of India.
[40] J. Stephenson,et al. Thromboprophylaxis patterns, risk factors, and outcomes of care in the medically ill patient population. , 2013, Thrombosis research.
[41] D. Cook,et al. Heparin Thromboprophylaxis in Medical-Surgical Critically Ill Patients: A Systematic Review and Meta-Analysis of Randomized Trials* , 2013, Critical care medicine.
[42] F. Violi,et al. Antithrombotic drugs in acutely ill medical patients: review and meta-analysis of interventional trials with low-molecular-weight heparin and fondaparinux , 2013 .
[43] J. Schein,et al. Incidence of venous thromboembolism in nursing home residents. , 2013, Journal of the American Medical Directors Association.
[44] R. Hull,et al. Venous Thromboembolism in Elderly High-Risk Medical Patients , 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[45] M. Cushman,et al. Venous thrombosis risk assessment in medical inpatients: the medical inpatients and thrombosis (MITH) study , 2013, Journal of thrombosis and haemostasis : JTH.
[46] P Prandoni,et al. Prevention and treatment of venous thromboembolism--International Consensus Statement. , 2013, International angiology : a journal of the International Union of Angiology.
[47] A. Mebazaa,et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. , 2013, The New England journal of medicine.
[48] Elie A Akl,et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. , 2013, Journal of clinical epidemiology.
[49] F. Rosendaal,et al. Pregnancy and travel-related thromboembolism. , 2013, Thrombosis research.
[50] D. Mukherjee,et al. Extended thromboprophylaxis for medically ill patients with decreased mobility: does it improve outcomes? , 2012, Journal of thrombosis and haemostasis : JTH.
[51] S. Cannegieter. Travel-related thrombosis. , 2012, Best practice & research. Clinical haematology.
[52] Günter Ollenschläger,et al. Guidelines International Network: Toward International Standards for Clinical Practice Guidelines , 2012, Annals of Internal Medicine.
[53] Elie A Akl,et al. Prevention of VTE in Nonsurgical Patients Antithrombotic Therapy and Prevention of Thrombosis , 9 th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines , 2013 .
[54] J. Brecht,et al. Cost Effectiveness of Enoxaparin as Prophylaxis against Venous Thromboembolic Complications in Acutely Ill Medical Inpatients , 2012, PharmacoEconomics.
[55] C. Cimminiello,et al. Low-molecular-weight heparin and mortality in acutely ill medical patients. , 2011, The New England journal of medicine.
[56] S. Goldhaber,et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. , 2011, The New England journal of medicine.
[57] Timothy J Wilt,et al. Venous Thromboembolism Prophylaxis in Hospitalized Medical Patients and Those With Stroke: A Background Review for an American College of Physicians Clinical Practice Guideline , 2011, Annals of Internal Medicine.
[58] P. Shekelle,et al. Venous Thromboembolism Prophylaxis in Hospitalized Patients: A Clinical Practice Guideline From the American College of Physicians , 2011, Annals of Internal Medicine.
[59] L. Lynd,et al. Low-Molecular-Weight Heparin Versus Unfractionated Heparin for Prophylaxis of Venous Thromboembolism in Medicine Patients—A Pharmacoeconomic Analysis , 2011, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[60] W. Zeng,et al. [The efficacy of intermittent pneumatic compression in the prevention of venous thromboembolism in medical critically ill patients]. , 2011, Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue.
[61] A. Turpie,et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. , 2011, Chest.
[62] P. Pronovost,et al. Are Sequential Compression Devices Commonly Associated With In-Hospital Falls? A Myth-Busters Review Using the Patient Safety Net Database , 2011, Journal of patient safety.
[63] Monica Acciarresi,et al. Efficacy and safety of anticoagulants in the prevention of venous thromboembolism in patients with acute cerebral hemorrhage: a meta‐analysis of controlled studies , 2011, Journal of thrombosis and haemostasis : JTH.
[64] G. Guyatt,et al. Dalteparin versus unfractionated heparin in critically ill patients. , 2011, The New England journal of medicine.
[65] G. Guyatt,et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. , 2011, Journal of clinical epidemiology.
[66] Gordon H Guyatt,et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. , 2011, Journal of clinical epidemiology.
[67] A. Turpie,et al. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. , 2011, Chest.
[68] S. Greenfield,et al. Clinical practice guidelines we can trust , 2011 .
[69] S. Greenfield,et al. COMMITTEE ON STANDARDS FOR DEVELOPING TRUSTWORTHY CLINICAL PRACTICE GUIDELINES , 2011 .
[70] H. Riess,et al. An open-label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN , 2010, Expert opinion on pharmacotherapy.
[71] P. Prandoni,et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score , 2010, Journal of thrombosis and haemostasis : JTH.
[72] M. Monreal,et al. Prolonged travel and venous thromboembolism findings from the RIETE registry. , 2010, Thrombosis research.
[73] E. Vicaut,et al. Extended-Duration Venous Thromboembolism Prophylaxis in Acutely Ill Medical Patients With Recently Reduced Mobility , 2010, Annals of Internal Medicine.
[74] H. Riess,et al. A randomized, double‐blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non‐surgical patients: CERTIFY Study , 2010, Journal of thrombosis and haemostasis : JTH.
[75] G. Guyatt,et al. The Vexing Problem of Guidelines and Conflict of Interest: A Potential Solution , 2010, Annals of Internal Medicine.
[76] E. Tangalos,et al. Thrombotic risk and immobility in residents of long-term care facilities. , 2010, Journal of the American Medical Directors Association.
[77] David B. Resnik,et al. Conflict of Interest in Medical Research, Education, and Practice , 2010, Environmental Health Perspectives.
[78] P. Sandercock,et al. Physical Methods for Preventing Deep Vein Thrombosis in Stroke , 2005, The Cochrane database of systematic reviews.
[79] P. Perel,et al. Thromboprophylaxis for trauma patients. , 2010, The Cochrane database of systematic reviews.
[80] H. Forta,et al. Prevention of Deep Venous Thrombosis and Pulmonary Embolism in Patients With Acute Intracerebral Hemorrhage , 2009, The neurologist.
[81] M. Galinski,et al. Gender as a risk factor for pulmonary embolism after air travel , 2009, Thrombosis and Haemostasis.
[82] H. Schünemann,et al. An official American Thoracic Society Policy statement: managing conflict of interest in professional societies. , 2009, American journal of respiratory and critical care medicine.
[83] D. Mozaffarian,et al. Meta-analysis: Travel and Risk for Venous Thromboembolism , 2009, Annals of Internal Medicine.
[84] J. Kline,et al. Risk of thromboembolism varies, depending on category of immobility in outpatients. , 2009, Annals of emergency medicine.
[85] P. Sandercock,et al. Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial , 2009, The Lancet.
[86] A. Amin,et al. Clinical and economic outcomes in patients at risk of venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis , 2009, Thrombosis and Haemostasis.
[87] K. Shojania,et al. How complete is the evidence for thromboembolism prophylaxis in general medicine patients? A meta-analysis of randomized controlled trials. , 2009, Journal of hospital medicine.
[88] F. Rosendaal,et al. Effect of elevated levels of coagulation factors on the risk of venous thrombosis in long-distance travelers. , 2009, Blood.
[89] R. Nieuwland,et al. Elevated platelet and leukocyte response to oral bacteria in periodontitis , 2009, Journal of thrombosis and haemostasis : JTH.
[90] A. Shorr,et al. Venous thromboembolism in critically ill patients , 2008, Thrombosis and Haemostasis.
[91] J. Benner,et al. Comparison of the two-year outcomes and costs of prophylaxis in medical patients at risk of venous thromboembolism , 2008, Thrombosis and Haemostasis.
[92] Clifford W Colwell,et al. Prevention of Venous Thromboembolism* American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th Edition) , 2008 .
[93] G. Guyatt,et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.
[94] J. Eikelboom. Effect of fondaparinux 2.5 mg once daily on mortality: a meta-analysis of phase III randomized trials of venous thromboembolism prevention , 2008 .
[95] J. Douketis,et al. Anticoagulant prophylaxis to prevent asymptomatic deep vein thrombosis in hospitalized medical patients: a systematic review and meta‐analysis , 2008, Journal of thrombosis and haemostasis : JTH.
[96] Samuel Z Goldhaber,et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study , 2008, The Lancet.
[97] F. Rosendaal,et al. Minor injuries as a risk factor for venous thrombosis. , 2008, Archives of internal medicine.
[98] J. Jansson,et al. Efficacy and safety of anticoagulant prophylaxis to prevent venous thromboembolism in acutely ill medical inpatients: a meta‐analysis , 2007, Journal of internal medicine.
[99] P. Sandercock,et al. Anticoagulants for acute ischaemic stroke. , 2008, The Cochrane database of systematic reviews.
[100] H. Büller,et al. Travel and venous thrombosis: a systematic review , 2007, Journal of internal medicine.
[101] J. Donovan,et al. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients. , 2007, Clinical therapeutics.
[102] H. Krum,et al. Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: a meta-analysis of randomized controlled trials. , 2007, Archives of internal medicine.
[103] P Duclos,et al. World Health Organization and International Travel and Health. , 2007, Travel medicine and infectious disease.
[104] C. Kase,et al. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison , 2007, The Lancet.
[105] J. Douketis,et al. Meta-analysis: Anticoagulant Prophylaxis to Prevent Symptomatic Venous Thromboembolism in Hospitalized Medical Patients , 2007, Annals of Internal Medicine.
[106] A. Shorr,et al. Low-molecular weight heparin for deep vein thrombosis prophylaxis in hospitalized medical patients: results from a cost-effectiveness analysis , 2005, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[107] G. Agnelli,et al. What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke? , 2007, Thrombosis research.
[108] A. Folsom,et al. Frailty and risk of venous thromboembolism in older adults. , 2007, The journals of gerontology. Series A, Biological sciences and medical sciences.
[109] A Eisinga,et al. Compression stockings for preventing deep vein thrombosis in airline passengers. , 2006, The Cochrane database of systematic reviews.
[110] Mir S. Siadaty,et al. Air Travel and Venous Thromboembolism: A Systematic Review , 2007, Journal of General Internal Medicine.
[111] M. Stokes,et al. Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients , 2006, Thrombosis journal.
[112] Luci K. Leykum,et al. Cost utility of substituting enoxaparin for unfractionated heparin for prophylaxis of venous thrombosis in the hospitalized medical patient. , 2006, Journal of hospital medicine.
[113] M. Perpiñá-Tordera,et al. Puede reducir la mortalidad de los pacientes con EPOC la profilaxis domiciliaria de la enfermedad tromboembólica venosa , 2006 .
[114] D. Nauffal-Manzur,et al. [Can home prophylaxis for venous thromboembolism reduce mortality rates in patients with chronic obstructive pulmonary disease?]. , 2006, Archivos de bronconeumologia.
[115] M. Prins,et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial , 2006, BMJ : British Medical Journal.
[116] H. Diener,et al. Prophylaxis of Thrombotic and Embolic Events in Acute Ischemic Stroke With the Low-Molecular-Weight Heparin Certoparin: Results of the PROTECT Trial , 2006, Stroke.
[117] I. Mahé,et al. Lack of effect of a low-molecular-weight heparin (nadroparin) on mortality in bedridden medical in-patients: a prospective randomised double-blind study , 2005, European Journal of Clinical Pharmacology.
[118] P. Stein,et al. Trends in the incidence of pulmonary embolism and deep venous thrombosis in hospitalized patients. , 2005, The American journal of cardiology.
[119] G. Velmahos,et al. Electrostimulation for the prevention of deep venous thrombosis in patients with major trauma: a prospective randomized study. , 2005, Surgery.
[120] S. Sansgiry,et al. Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients. , 2005, The American journal of managed care.
[121] E. Voth,et al. Heparin therapy, deep-vein thrombosis and pulmonary embolism after intracerebral hemorrhage , 1988, Klinische Wochenschrift.
[122] G. Guyatt,et al. Systems for grading the quality of evidence and the strength of recommendations I: Critical appraisal of existing approaches The GRADE Working Group , 2004, BMC health services research.
[123] S. Goldhaber,et al. Randomized, Placebo-Controlled Trial of Dalteparin for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients , 2004, Circulation.
[124] H. Yanar,et al. Venous Thromboembolism Prophylaxis after Head and Spinal Trauma: Intermittent Pneumatic Compression Devices Versus Low Molecular Weight Heparin , 2004, World Journal of Surgery.
[125] A. Lloyd,et al. Economic evaluation of enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients , 2004, Pharmacy World and Science.
[126] Paul Enright,et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. , 2004, The American journal of medicine.
[127] S. Cohn,et al. Randomized clinical trial of intermittent pneumatic compression and low molecular weight heparin in trauma , 2003, The British journal of surgery.
[128] Andrew D Oxman,et al. Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[129] C. Witt,et al. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. , 2003, American heart journal.
[130] M. Kaste,et al. Enoxaparin vs heparin for prevention of deep‐vein thrombosis in acute ischaemic stroke: a randomized, double‐blind study , 2002, Acta neurologica Scandinavica.
[131] L. Melton,et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. , 2002, Archives of internal medicine.
[132] J. Heit. Venous Thromboembolism Epidemiology: Implications for Prevention and Management , 2002, Seminars in thrombosis and hemostasis.
[133] A. Gafni,et al. Economic evaluation of the MEDENOX trial: a Canadian perspective. Medical Patients with Enoxaparin. , 2002, Canadian respiratory journal.
[134] A. Nicolaides,et al. Venous Thrombosis from Air Travel: The LONFLIT3 Study , 2002, Angiology.
[135] P. Sandercock,et al. Low-Molecular-Weight Heparins or Heparinoids Versus Standard Unfractionated Heparin for Acute Ischemic Stroke , 2005 .
[136] A. Lloyd,et al. Economic evaluation of the use of enoxaparin for thromboprophylaxis in acutely ill medical patients , 2001 .
[137] F. Fagnani,et al. Economic evaluation of enoxaparin vs. placebo for the prevention of venous thromboembolism in acutely ill medical patients. , 2000, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[138] S. Goldhaber,et al. Low molecular weight heparin versus minidose unfractionated heparin for prophylaxis against venous thromboembolism in Medical Intensive Care Unit patients A randomized controlled trial , 2000 .
[139] R. Pordes,et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. , 2000, American journal of respiratory and critical care medicine.
[140] Y. Kupfer,et al. Subcutaneous Heparin Prophylaxis Significantly Reduces The Incidence Of Venous Thromboembolic Events In The Critically Ill , 1999 .
[141] A. Turpie,et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. , 1999, The New England journal of medicine.
[142] B. Meyer. Antithrombotic Drugs:Insights f rom Cardiology , 1998, Cerebrovascular Diseases.
[143] Peter Sandercock,et al. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke , 1997, The Lancet.
[144] J. Bergmann,et al. A Multicenter Randomized Double-blind Study of Enoxaparin Compared with Unfractionated Heparin in the Prevention of Venous Thromboembolic Disease in Elderly In-patients Bedridden for an Acute Medical Illness , 1996, Thrombosis and Haemostasis.
[145] M. Knudson,et al. Use of low molecular weight heparin in preventing thromboembolism in trauma patients. , 1996, The Journal of trauma.
[146] B. Gårdlund,et al. Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases , 1996, The Lancet.
[147] W. Schramm,et al. The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). The Prime Study Group. , 1996, Haemostasis.
[148] A. Ahuja,et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke , 1995 .
[149] P Landau,et al. Deep vein thrombosis: prevention in stroke patients during rehabilitation. , 1995, Archives of physical medicine and rehabilitation.
[150] C. Fisher,et al. Effectiveness of Pneumatic Leg Compression Devices for the Prevention of Thromboembolic Disease in Orthopaedic Trauma Patients: A Prospective, Randomized Study of Compression Alone Versus no Prophylaxis , 1995, Journal of orthopaedic trauma.
[151] J. Egberts,et al. A multicentre, double-blind, randomized study to compare the safety and efficacy of once-daily ORG 10172 and twice-daily low-dose heparin in preventing deep-vein thrombosis in patients with acute ischaemic stroke. , 1994, Age and ageing.
[152] F. Lewis,et al. Prevention of venous thromboembolism in trauma patients. , 1994, The Journal of trauma.
[153] W. Fallon,et al. Efficacy of deep venous thrombosis prophylaxis in trauma patients and identification of high-risk groups. , 1992, The Journal of trauma.
[154] M. Gent,et al. A Low-Molecular-Weight Heparinoid Compared with Unfractionated Heparin in the Prevention of Deep Vein Thrombosis in Patients with Acute Ischemic Stroke , 1992, Annals of Internal Medicine.
[155] M. Knudson,et al. Thromboembolism following multiple trauma. , 1992, The Journal of trauma.
[156] P. Sandset,et al. A double-blind and randomized placebo-controlled trial of low molecular weight heparin once daily to prevent deep-vein thrombosis in acute ischemic stroke. , 1990, Seminars in thrombosis and hemostasis.
[157] A. Serradimigni,et al. Prévention des thromboses veineuses profondes des membres inférieurs par une fraction d'héparine de très bas poids moléculaire (CY 222) chez des patients porteurs d'une hémiplégie secondaire à un infarctus cérébral: étude pilote randomisée (30 patients) , 1990 .
[158] R. Khalil,et al. [Prevention of deep venous thrombosis of the leg by a very low molecular weight heparin fraction (CY 222) in patients with hemiplegia following cerebral infarction: a randomized pilot study (30 patients)]. , 1990, La Revue de medecine interne.
[159] M. Prins,et al. Prophylaxis of deep venous thrombosis with a low-molecular-weight heparin (Kabi 2165/Fragmin) in stroke patients. , 1989, Haemostasis.
[160] C. Ibarra-Pérez,et al. Prevalence and Prevention of Deep Venous Thrombosis of the Lower Extremities in High-Risk Pulmonary Patients , 1988, Angiology.
[161] A. Turpie,et al. Intravenous heparin for the prevention of stroke progression in acute partial stable stroke. , 1986, Annals of internal medicine.
[162] M. M. Fukujima,et al. Prevention of Deep Venous Thrombosis and Pulmonary Embolism , 1986, The Lancet.
[163] S. McCarthy,et al. Low-dose subcutaneous heparin in the prevention of deep-vein thrombosis and pulmonary emboli following acute stroke. , 1986, Age and ageing.
[164] C. Caulin,et al. Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: a randomized double-blind trial. , 1986, Haemostasis.
[165] E. Salzman,et al. Prevention of venous thromboembolism in unstable angina pectoris. , 1982, The New England journal of medicine.
[166] A. Banerjee,et al. Incidence of deep vein thrombosis and the effect of pneumatic compression of the calf in elderly hemiplegics. , 1982, Age and ageing.
[167] C. Forbes,et al. Prevention of Deep Vein Thrombosis in Medical Patients by Low-Dose Heparin , 1981, Scottish medical journal.
[168] C. Hawkey,et al. LOW-DOSE HEPARIN AS A PROPHYLAXIS AGAINST DEEP-VEIN THROMBOSIS AFTER ACUTE STROKE , 1977, The Lancet.
[169] R. J. Tuttle,et al. Small subcutaneous doses of heparin in prevention of venous thrombosis. , 1973, The New England journal of medicine.
[170] C. Dolea,et al. World Health Organization , 1949, International Organization.